Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Bristol myers squibb - The Untold Story

Two Drugmakers Have Paused Autoimmune CAR T Cell Trials After Three Deaths from a Severe Immune Reaction

Novartis paused eight autoimmune CAR T trials after three severe immune reactions, and Bristol Myers Squibb paused enrollment in its program.

Medical Daily

BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

Barchart

FDA Clears a New Class of Myeloma Drug for Patients Whose Cancer Returned After Earlier Treatment

The FDA granted accelerated approval to iberdomide, the first CELMoD for relapsed multiple myeloma, usable as early as first relapse.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Soriot should explain the curious case of AstraZeneca’s non-deal

AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders

The Guardian - UK

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling

The Guardian - UK

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.

Benzinga

AstraZeneca in talks over £300bn mega-merger with US rival – reports

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca share prices drop amid £300bn mega-merger talks with US rival

The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company

The Independent UK

AstraZeneca falls to third-largest UK company amid US merger talks

Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale

The Guardian - UK

Hallucinations in Alzheimer's Still Have No Approved Treatment, and the Biggest Trial Program Just Slipped to 2027

Bristol Myers Squibb delayed its Alzheimer's psychosis trial readouts to 2027. Why the treatment gap matters for families managing symptoms now.

Medical Daily

Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now

As investors rotate toward value, Altria, Bristol Myers Squibb, and American Electric Power stand out as reliable dividend stocks with strong payout growth histories and defensive appeal.

MarketBeat

Pfizer and the $200 Billion-Dollar Cardiovascular Market

Pfizer's cardiovascular business highlights the intersection of drug pricing, marketing, patents, and competition in the rapidly growing $200 billion heart disease market.

International Business Times

Bristol Myers buys Nvidia's latest AI computing system for drug research

Bristol Myers Squibb is buying Nvidia's latest AI computing system. This new system will support artificial intelligence in drug discovery and development. The company expects to cycle through many more potential drug candidates faster. AI tools are already cutting drug testing times by twenty to thirty percent. This investment drives…

The Economic Times

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise

Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS program and recent clinical data in hypertrophic cardiomyopathy during a discussion hosted by RBC Capi

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential

Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist. Sp

MarketBeat

2 Buffett Stocks to Load Up On—And 1 to Ditch

With Buffett having officially stepped down at Berkshire Hathaway, investors might continue to follow his lead when it comes to these popular names.

Benzinga

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

Benzinga

Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities

Bristol Myers Squibb Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition

Bristol Myers Squibb Co. (NYSE:BMY) on Friday agreed to acquire Orbital Therapeutics, a privately held biotechnology company focused on RNA medicines that reprogram the immune system in vivo.

Benzinga

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients

Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM).

Fortune

Mass shooting in central business district shakes Manhattan, leaves at least 4 dead

345 Park Avenue hosts Blackstone, the world’s largest alternative asset manager, the NFL, KPMG, and Bristol Myers Squibb, among others.

Benzinga

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Fortune

DEI is emerging triumphant in shareholder battles across at companies ranging from Coca-Cola to Berkshire Hathaway

Here’s what happened to anti-DEI proposals put before shareholders at several U.S. companies, including Apple, Goldman Sachs, and Costco.

Fortune

Inside the futuristic biotech startup Cellares that’s building a cure for cancer with $355 million in funding

Why New Jersey is a hub for biotech manufacturing.

Evening Standard

People with blood cancer to benefit from innovative new treatment on the NHS

The type of Car T-cell therapy involves taking a patient’s T-cells and modifying them.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.